SAFETY-FLAG // NO-HUMAN-DATA
BPC-157 TB-500 Side Effects and Safety: What the Research Actually Shows
Long-term human safety is unknown for both constituents and for the blend. One safety signal is flagged honestly: Thymosin Beta-4's pro-angiogenic, pro-migratory properties are implicated in tumor metastasis. This page reads that record straight.
The safety record, shown straight
BPC-157 TB-500 side effects cannot be read off a controlled human safety study, because none exists for the blend or for the TB-500 fragment. That absence is the first and most important entry on the safety record, and this page states it before anything else [8][9].
What exists is bounded. BPC-157 has three small human pilot studies and no controlled safety trial; a 2025 systematic review found "no clinical safety data" across its 36-study base [8]. "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide that is actually sold [7]. A 2026 Sports Medicine review of approved and unapproved musculoskeletal peptides lists both BPC-157 and TB-500 and cautions that rigorous human safety data are scarce, with potential for serious harm, for compounds operating largely outside regulatory oversight [9]. Combining two unapproved peptides does not average their uncertainty — it compounds it.
What are the side effects of BPC-157 and TB-500?
Long-term human safety is unknown for both constituents. The main flagged concern is a theoretical tumor and angiogenesis signal for Thymosin Beta-4, and combining two unapproved peptides compounds the uncertainty [4][9]. Component human exposure is limited — three small BPC-157 pilots and full-length Thymosin Beta-4 Phase 1 work — and no controlled safety data exist for the assembled blend [8][9].
The Thymosin Beta-4 tumor/angiogenesis safety signal
The one specific, literature-grounded safety signal for this blend comes through its TB-500 specimen. Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis [5]. The same pro-migratory, pro-angiogenic properties that aid tissue repair are the properties a tumor uses to spread and to recruit blood supply — so a signal that is helpful in a healing wound is the signal of concern in a malignancy [5][4].
This is a flagged consideration, not a demonstrated effect of the blend in humans. No carcinogenicity data exist for the combination, and the association is drawn from tumor-model and cell-line work on Thymosin Beta-4, which is overexpressed in several cancers [5]. The reason it is foregrounded here rather than buried is structural: when two pro-repair peptides are combined, a pro-angiogenic, pro-migratory concern is the kind of signal that compounds rather than cancels [4].
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [5]. This is a flagged safety consideration drawn from tumor-model research, not a demonstrated human effect of the blend; no carcinogenicity data exist for the combination [5][8].
Mixed and null preclinical results that temper the recovery story
An honest safety brief also surfaces the results that cut against the marketing narrative — the mixed and null findings that the "rapid healing of anything" claims tend to omit [4].
The clearest is the dystrophin-deficient mdx study. Mice given 150 microg of Thymosin Beta-4 intraperitoneally twice weekly for six months showed a significant increase in the number of regenerating skeletal-muscle fibers — but no improvement in muscle strength or cardiac function, and fibrosis remained elevated [6]. More regenerating fibers did not translate into a functional gain. A dose-response result points the same way: in a rat embolic-stroke study, Thymosin Beta-4 dosing was non-monotonic, with 18 mg/kg giving no benefit, which undermines "more is better" loading rationales [4].
Is the BPC-157 / TB-500 blend safe for long-term use?
No long-term controlled human data exist for either constituent or the blend [8][9]. The mdx study showed chronic Thymosin Beta-4 produced more regenerating fibers but no gain in strength, cardiac function, or fibrosis reduction [6]; recent reviews rate the human evidence as scarce and treat the compounds as investigational [8][10]. "Long-term safe" is not a claim the published record supports.
What recent reviews say, and the doubled identity caveat
The most defensible reading of safety is review-level, and recent reviews are uniformly cautious about both constituents [8][9][10].
What do doctors and reviews say about the BPC-157 + TB-500 blend?
Recent reviews are cautious. A 2025 systematic review rated BPC-157 evidence at the lowest tiers (level IV-V) with "no clinical safety data" and no combination mention [8]; a 2026 Sports Medicine review flagged scarce human safety data and potential for serious harm for unapproved musculoskeletal peptides including BPC-157 and TB-500 [9]; and a 2025 narrative review concluded BPC-157 should be considered investigational given limited human data and non-regulated availability [10].
A second caveat doubles the uncertainty on the TB-500 specimen specifically. "TB-500" as sold is the Ac-LKKTETQ heptapeptide (~889 Da), but the overwhelming majority of efficacy and tolerability data attributed to it were generated with full-length Thymosin Beta-4 (~4963 Da) [4][7]. A safety read of the blend therefore inherits a gap on one of its two specimens — it is leaning on parent-protein data for a fragment that has not itself been characterized in controlled human safety work. Layered on top is the unregulated-product problem: identity, purity, and the actual BPC-157:TB-500 ratio in marketed "Wolverine" material are not guaranteed outside formal studies [3]. The present-tense regulatory status of both peptides sits on Wolverine legal status and 503A compounding, and the full record is in the full reference list.